tm logo
DELVE
Live/Pending
SUSPENSION LETTER - MAILED

mailed

on 27 Jun 2024

Last Applicant/ Owned by

55 CAMBRIDGE PARKWAY, SUITE 800E

CAMBRIDGE

MA

02142

Serial Number

98254371 filed on 03rd Nov 2023

Registration Number

N/A

Correspondent Address

Christina M. Licursi

Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.

BOSTON, MA 02210-2206

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

DELVE

Medical research and development; research and development in the field of computational biology, bioinformatics, genetics, genomics, biotechnology, pharmaceuticals, and therapeutics; platform as a service (PaaS) featuring computer software platforms for drug discovery; pharmaceutical and biopharmaceutical research and development; drug development services, namely, pharmaceutical drug development Read More

Classification Information


Class [042]
Computer & Software Services & Scientific Services


Medical research and development; research and development in the field of computational biology, bioinformatics, genetics, genomics, biotechnology, pharmaceuticals, and therapeutics; platform as a service (PaaS) featuring computer software platforms for drug discovery; pharmaceutical and biopharmaceutical research and development; drug development services, namely, pharmaceutical drug development services; development of pharmaceuticals and therapeutic agents for others, namely, development of pharmaceutical preparations and medicines; platform as a service (PaaS) featuring computer software platforms for enabling research and development of pharmaceutical data in the field of computational biology, bioinformatics, genetics, genomics, biotechnology and pharmaceuticals; DNA, RNA, and genomic analysis and sequencing services for medical research purposes; none of the foregoing relating to finding people scientific studies to participate in or recruiting participants for scientific studies


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceuticals for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 98254371

Mark Type

No Service Mark

Attorney Docket Number

No F20782000200

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
27th Jun 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
27th Jun 2024SUSPENSION LETTER WRITTEN
27th Jun 2024LETTER OF SUSPENSION E-MAILED
04th Jun 2024TEAS/EMAIL CORRESPONDENCE ENTERED
03rd Jun 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
03rd Jun 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
04th Mar 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
04th Mar 2024NON-FINAL ACTION E-MAILED
04th Mar 2024NON-FINAL ACTION WRITTEN
26th Jan 2024TEAS/EMAIL CORRESPONDENCE ENTERED